Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Repligen Corporation (RGEN)
Repligen Corporation stock price live, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Repligen Corporation real time stock price chart below.
What Is the Repligen Corporation Stock Price Today?
The Repligen Corporation stock price today is 149.06.
What Is the Stock Symbol for Repligen Corporation?
The stock symbol for Repligen Corporation is ""RGEN.""
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
What Is the Repligen Corporation Stock Price Today?
The Repligen Corporation stock price today is 149.06.
What Is the Stock Symbol for Repligen Corporation?
The stock symbol for Repligen Corporation is ""RGEN.""
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
Fair Value
An estimate of a Repligen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
144.21
153.48
52 wk Range
102.96
182.52
RGEN Scorecard
Full Analysis
Net income is expected to grow this year
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Repligen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
144.21153.48
52 wk Range
102.96182.52
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Repligen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
187.00
Upside
+25.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Repligen Corporation For: 28 October
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Repligen Corporation Company Profile
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation SWOT Analysis
Bioprocessing Pionee | Repligen leads the $12B bioprocessing market with innovative technologies, strategic acquisitions, and a focus on new modalities driving growth |
Financial Resilience | Despite market challenges, Repligen maintains strong financials with a 51.15% gross profit margin and upward revenue guidance for 2025 |
Market Dominance | Explore Repligen's unique position, with 80% of its portfolio facing little to no competition, fostering pricing power and market leadership |
Future Trajectory | Analyst targets range from $150 to $220, reflecting varied views on Repligen's growth potential amid industry recovery and expansion |
Repligen Corporation Earnings Call Summary for Q3/2025
- Q3 revenue up 22% YoY to $189M, beating forecasts. Adjusted EPS of $0.46 exceeded expectations by 9.52%.
- Stock rose 2.42% to $165 in pre-market trading. Full-year revenue guidance raised to $729-$737 million.
- Strong performance driven by 18% organic growth and strategic investments, particularly in Asia Pacific region.
- CEO highlights success in acquiring late-stage commercial customers and aims to outpace industry growth by 5%.
- Company sees opportunities in onshoring projects, digitization, and process analytics for future growth.
Last Updated: 28/10/2025, 14:56
Read Full TranscriptCompare RGEN to Peers and Sector
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | 4,824.9x | −3.0x | −0.7x | |
PEG Ratio | 2.52 | −0.02 | 0.00 | |
Price/Book | 4.1x | 1.8x | 2.6x | |
Price / LTM Sales | 11.8x | 3.1x | 3.4x | |
Upside (Analyst Target) | 24.5% | 80.0% | 39.3% | |
Fair Value Upside | Unlock | 23.1% | 5.7% | Unlock |
Analyst Ratings
16 Buy
5 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 187.00
(+25.45% Upside)
Earnings
Latest Release
Oct 28, 2025
EPS / Forecast
0.46 / 0.42
Revenue / Forecast
189.00M / 181.78M
People Also Watch
FAQ
What Stock Exchange Does Repligen Trade On?
Repligen is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Repligen?
The stock symbol for Repligen is "RGEN."
What Is the Repligen Market Cap?
As of today, Repligen market cap is 8.39B.
What Is Repligen's Earnings Per Share (TTM)?
The Repligen EPS (TTM) is 0.03.
When Is the Next Repligen Earnings Date?
Repligen will release its next earnings report on 24 Feb 2026.
From a Technical Analysis Perspective, Is RGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Repligen Stock Split?
Repligen has split 0 times.
How Many Employees Does Repligen Have?
Repligen has 1778 employees.
What is the current trading status of Repligen (RGEN)?
As of 01 Nov 2025, Repligen (RGEN) is trading at a price of 149.06, with a previous close of 144.57. The stock has fluctuated within a day range of 144.21 to 153.48, while its 52-week range spans from 102.96 to 182.52.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.